300+ investors in your industry, stage, and region Get
Any industry
Artificial Intelligence
Google
EdTech
Clean Energy
Retail
Enterprise Software
Local
Platforms
Travel
InsurTech
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Organic Food
Email
Fitness
CleanTech
Energy
Health Care
Machine Learning
Agriculture (AgTech)
Marketplace
Gaming
Facebook
Blockchain
B2B
Social Network
Big Data
Video Games
Education
Wellness
Medical Device
Mobile
Construction
Automotive
Legal
Sports
eSports
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Theatre
Recruiting
Crowdfunding
Web3
Medical
Fashion
Social
Venture Capital
Infrastructure
Beauty
Celebrity
Cannabis
Climate
LGBT
Publishing
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Music
Real Estate
Art
Sporting Goods
Digital Media
Finance
Manufacturing
FinTech
Social Media
Financial Services
Franchise
Non Profit
Mobile Advertising
Internet
Android
Biotech
Proptech
Sustainability
Hardware
Transportation
Impact
Enterprise
Community
Media (Entertainment)
Any country
Burkina Faso
South Korea
Africa
LATAM
Singapore
Brazil
Saudi Arabia
Oceania
Greece
Gibraltar
Norway
Liberia
Mexico
Taiwan
Sweden
Zambia
Puerto Rico
Tunisia
Russian Federation
Togo
Tajikistan
Zimbabwe
Nigeria
Guinea
Nepal
Iran
Kyrgyzstan
Isle of Man
Pakistan
Oman
Romania
Cameroon
New Zealand
Colombia
Australia
China
Sri Lanka
Armenia
Costa Rica
Switzerland
Czech Republic
Kenya
Cayman Islands
Kuwait
Kazakhstan
Jamaica
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uganda
Turkey
Uzbekistan
Venezuela
Guatemala
Malawi
Moldova
United Kingdom
Seychelles
Botswana
Japan
South Africa
Egypt
France
Georgia
Denmark
Croatia
Hong Kong
Ghana
Iraq
Mali
Morocco
Myanmar
Latvia
Malaysia
Poland
Philippines
Portugal
Sierra Leone
Rwanda
El Salvador
Senegal
Thailand
Uruguay
Tanzania
Canada
India
Germany
Ireland
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Cyprus
Qatar
United Arab Emirates
Spain
Europe
Angola
Argentina
Bangladesh
Barbados
Belgium
Ethiopia
Jordan
Austria
Azerbaijan
Ecuador
Bulgaria
Bahrain
Bahamas
Faroe Islands
Jersey
Estonia
Bolivia
Algeria
Belize
Belarus
Finland
Italy
Hungary
Israel
Grenada
Honduras
Iceland
Cambodia
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotechnology Startup Investors in Belgium (July 2026)

The most active venture capital funds and angel investors investing in Belgium Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Belgium Biotechnology startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
PMV
VC Fund
18 Belgium, United States, The Netherlands Series A, Seed Software, Biotechnology, Health Care $549k–$40M
V-Bio Ventures
VC Fund
15 Belgium, France, United States Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $3.1M–$88M
Gemma Frisius Fund
VC Fund
15 Belgium, France, United Kingdom Seed, Series A, Series B Biotechnology, Health Care, Medical $384k–$84M
Meusinvest (Noshaq)
VC Fund
14 Belgium, France, Germany Series A, Seed Biotechnology, Health Care, Medical $137k–$16M
S.R.I.W.
VC Fund
13 Belgium, United States, Spain Series A, Series B Health Care, Biotechnology, Manufacturing $411k–$75M
Qbic Fund
VC Fund
12 Belgium, The Netherlands Seed, Series A Biotechnology, Software, Health Care $868k–$28M
VIB
VC Fund
12 Belgium, Brazil, Denmark Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $3.1M–$84M
Vives Louvain Technology Fund
VC Fund
9 Belgium, France, United States Series A, Series B Health Care, Biotechnology, Medical $491k–$125M
Limburgse Reconversie Maatschappij
VC Fund
8 Belgium, United States, The Netherlands Seed, Series A Information Technology, Software, Biotechnology $494k–$11M
Gimv
VC Fund
8 Belgium, United States, France Series B, Series A Biotechnology, Health Care, Medical $3.3M–$79M
Capricorn Partners
VC Fund
8 Belgium, The Netherlands, United States Series A, Series B Biotechnology, Software, Health Care $3.3M–$42M
Vesalius Biocapital Partners
VC Fund
7 Belgium, Germany, France Series A, Series B, Series C Biotechnology, Health Care, Medical $3.8M–$100M
Newton Biocapital
VC Fund
7 Belgium, Japan, France Series A, Seed Biotechnology, Medical, Health Care $2.7M–$84M
EQT Life Sciences
VC Fund
6 United States, The Netherlands, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $6.9M–$165M
Sambrinvest
VC Fund
6 Belgium, France, Spain Seed, Series A, Series B Biotechnology, Health Care, Medical $411k–$46M
KBC
VC Fund
4 Belgium, United States, The Netherlands Seed, Series A, Series B Biotechnology, Health Care, FinTech $549k–$65M
Boehringer Ingelheim Venture Fund
VC Fund
4 United States, Germany, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $1.8M–$50M
Baekeland Funds
VC Fund
4 Belgium Series B, Series C Biotechnology, Hardware, Software
Omnes Capital
VC Fund
4 France, Germany, United States Series A, Series B Software, Biotechnology, Health Care $3.5M–$53M
Annie Vereecken
Angel
4 Belgium Seed, Series A Medical, Biotechnology, Hospital $2M–$27M
Droia Ventures
VC Fund
4 United States, Belgium, The Netherlands Series A, Series B, Series C Biotechnology, Medical, Therapeutics $15M–$125M
Spinventure
VC Fund
4 Belgium Series A Health Care, Biotechnology, Medical $768k–$15M
Novo Holdings
VC Fund
4 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $9M–$135M
Inventures SA
VC Fund
3 Belgium, France, United Kingdom Series A, Seed Health Care, Biotechnology, Manufacturing $82k–$13M
Forbion Capital Partners
VC Fund
3 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $16M–$176M
VIVES Funds
VC Fund
3 Belgium, France, Switzerland Series A, Seed, Series B Biotechnology, Health Care, Therapeutics $2.9M–$165M
Agri Investment Fund
VC Fund
3 Belgium, Switzerland, United Kingdom Series B, Seed, Series A Biotechnology, Agriculture, AgTech $3.7M–$24M
Fountain Healthcare Partners
VC Fund
3 Ireland, United States, France Series A, Series B, Series C Health Care, Biotechnology, Medical $3.3M–$110M
Fund+
VC Fund
3 Belgium, United States, Spain Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $11M–$401M
Mérieux Equity Partners
VC Fund
3 France, United States, Belgium Series A, Private Equity Health Care, Biotechnology, Medical Device $5.7M–$150M
UCB Ventures
VC Fund
3 United States, Belgium, Spain Series A, Series B, Seed Biotechnology, Health Care, Medical $1.8M–$135M
AdBio partners
VC Fund
3 France, Spain, Belgium Seed, Series A Biotechnology, Health Care, Pharmaceutical $2.2M–$37M
SFPIM
VC Fund
3 Belgium, France, Switzerland Series A, Venture - Series Unknown Biotechnology, Health Care, AgTech $8.6M–$251M
BioGeneration Ventures
VC Fund
3 The Netherlands, United States, Belgium Series A, Seed Biotechnology, Therapeutics, Health Care $1.1M–$86M
Sofinnova Partners
VC Fund
2 France, United States, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $6.6M–$109M
HTGF (High-Tech Gruenderfonds)
VC Fund
2 Germany, Switzerland, United States Seed, Series A Software, Biotechnology, Information Technology
Sofinnova Investments
VC Fund
2 United States, France, Switzerland Series B, Series A, Series C Biotechnology, Health Care, Pharmaceutical $7.3M–$150M
Qbic
VC Fund
2 Belgium Seed, Series B Health Care, Biotechnology, AgTech $3.7M–$12M
Capital-E
VC Fund
2 Belgium, United States, Germany Series B, Series A Software, Manufacturing, Semiconductor $3.3M–$26M
Theodorus III
VC Fund
2 Belgium, Canada, France Seed, Series A Health Care, Life Science, Biotechnology $2.2M–$18M
Quest for Growth
VC Fund
2 Belgium, France, The Netherlands Series B, Series C Biotechnology, Hardware, Software $510k–$65M
M Ventures
VC Fund
2 United States, United Kingdom, Switzerland Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.4M–$100M
Pontifax
VC Fund
2 United States, Israel, France Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $6.3M–$128M
Thuja Capital
VC Fund
2 The Netherlands, Belgium, United States Series A, Seed Biotechnology, Medical, Health Care
Eli Lilly
VC Fund
2 United States, United Kingdom, Canada Series A, Series B Biotechnology, Health Care, Medical
SFPI-FPIM
VC Fund
2 Belgium, United States, France Series B, Series A Health Care, Biotechnology, Medical Device
GoBeyond
VC Fund
2 Switzerland, Germany, United Kingdom Seed, Series A Information Technology, Medical, Software
Luc Vauterin
Angel
2 Belgium Seed, Series A Life Science, Data Integration, Data Visualization
invest.bw
VC Fund
2 United States Seed Health Care, Neuroscience
Johnson & Johnson Innovation
VC Fund
2 United States, Israel, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Medical $4.4M–$150M
Access all 277 investors in Belgium Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

PMV
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 18 investments in Belgium Biotechnology startups

Do and dare company

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Seed
  • Geography: Belgium, United States, The Netherlands

Investor stats

  • Total investments: 152
  • Round size: Seed $549k–$4.3M; Series A $2.7M–$40M
  • Lead/follow: 22% lead, 78% follow

Portfolio highlights

  • Animab — Animal Health Company
  • Sentea — Sentea makes fibre optic Sensing affordable to the industry and enables continuous monitoring even in harsh environments.
  • CHILI publish — Allow users to edit customizable documents, or fully automate artwork generation. Output files are ready to use for print and digital.
Show all investments...

V-Bio Ventures
VC Fund · Gent, Oost-Vlaanderen, Belgium · 15 investments in Belgium Biotechnology startups

V-Bio Ventures is an independent venture capital firm specialized in building and financing young, innovative life science companies. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biotech, pharmaceutical and agriculturalsectors.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: Belgium, France, United States

Investor stats

  • Total investments: 43
  • Round size: Seed $3.1M–$50M; Series A $6.6M–$70M; Series B $12M–$88M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — raised $129M in 2021

Portfolio highlights

  • Animab — Animal Health Company
  • Step Pharma — Step Pharma is a spin-off of Imagine Institute stemming from Pr. Alain Fischer’s research on genetic immunodeficiencies. Step Pharma is a joint venture between Imagine, a research and innovative healthcare institute, Sygnature Discovery, a leading provider of integrated drug discovery resource and expertise, and Kurma Partners, a major player inthe funding of healthcare and biotechnology in Europe.
  • Biodol Therapeutics — Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (CyrilRivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
Show all investments...

Gemma Frisius Fund
VC Fund · Leuven, Vlaams-Brabant, Belgium · 15 investments in Belgium Biotechnology startups

Gemma Frisius Fund KU Leuven is a seed capital fund that aims to stimulate the creation and growth of university related spin-off companies.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: Belgium, France, United Kingdom

Investor stats

  • Total investments: 39
  • Round size: Seed $384k–$4.6M; Series A $932k–$84M; Series B $4.4M–$24M
  • Lead/follow: 10% lead, 90% follow

Portfolio highlights

  • Runeasi — The first scientifically validated wearable solution to measure impact while running and detect how your body responds to it - Perform real-time biomechanical assessments - Guide your athletes and patients with actionable insights to help them run more efficiently and recover from injuries with confidence
  • Aspect Analytics — Aspect Analytics offers consultancy services, home-grown software, development of workflows, and customization of software.
  • Magics Technologies — Magics Technologies is a nuclear research center that develops autonomous machines for sustainable energy sources.
Show all investments...

Meusinvest (Noshaq)
VC Fund · Liège, Liege, Belgium · 14 investments in Belgium Biotechnology startups

Noshaq offers financial services to help businesses develop.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Seed
  • Geography: Belgium, France, Germany

Investor stats

  • Total investments: 77
  • Round size: Seed $137k–$6M; Series A $3.3M–$16M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • TrustUp — TrustUp is the home contractors platform, connects homeowners with verified quality home improvement.
  • Le Fourgon — Le Fourgon provides contained drinks for home delivery. They offer milk, water, beer, wine, fruit juice, and sodas. They allow customers to have their drinks delivered free of charge during the day.
  • Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Show all investments...

S.R.I.W.
VC Fund · Liège, Liege, Belgium · 13 investments in Belgium Biotechnology startups

The S.R.I.W. Group is an institution at the heart of the financial market that assists entrepreneurs in creating and developing businesses in the Walloon region. It reflects the effort of Wallonian industry in facing the challenges of the creation of economic value in the 21st century. Since its creation in 1979, the Société Régionaled’Investissement de Wallonie has continuously been expanding its abilities to adapt and anticipate as well as its flexibility in order to meet the requirements of its partners who are confronted with the evolution of the world economy. The principles of good governance, a strong business culture and shared values at the heart of the Group constitute important assets to capture the changing realities of the market and progress in a sustainable development perspective.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Series A, Series B
  • Geography: Belgium, United States, Spain

Investor stats

  • Total investments: 111
  • Round size: Series A $411k–$31M; Series B $1.6M–$75M
  • Lead/follow: 21% lead, 79% follow

Portfolio highlights

  • Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
  • Intressa Vascular — Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection.
  • Santero Therapeutics — This is the homepage of the website
Show all investments...

Qbic Fund
VC Fund · Belgium, Wisconsin, United States · 12 investments in Belgium Biotechnology startups

The Qbic Fund is a multi-sector fund supporting spin-off companies of the Ghent, Brussels and Antwerp university associations and of VITO. Through its strategic partnership with the universities of Ghent, Brussels and Antwerp, and VITO, the Qbic Fund has early and privileged access to promising research projects at these partner universities. Ourinvestment approach is based on early in-depth and independent review and analysis followed by hands on involvement and support.In May 2012 the Qbic Fund held its first close and currently it has over € 30 million under management. The Qbic Fund is backed by several public and private investors and managed by Qbic Venture Partners.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series A
  • Geography: Belgium, The Netherlands

Investor stats

  • Total investments: 57
  • Round size: Seed $1.3M–$7.7M; Series A $868k–$28M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: Likely still investing — raised $57M in 2022

Portfolio highlights

  • Aloxy — Aloxy offers reliable IIot solutions tailored to the needs of the process industry. Our valve sensor provides an open and close indication of manual valves.
  • Accelleran — Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet.
  • Blue Foot Membranes — Blue Foot Membranes delivers unbreakable MBR membranes for wastewater treatment. Reliable water reuse, high capacity and low total cost of ownership.
Show all investments...

VIB
VC Fund · Gent, Oost-Vlaanderen, Belgium · 12 investments in Belgium Biotechnology startups

Strategic research in on life sciences and biotechnology

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: Belgium, Brazil, Denmark

Investor stats

  • Total investments: 25
  • Round size: Seed $3.1M–$11M; Series A $6.8M–$84M; Series B $4.4M–$65M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
  • MRM Health NV — MRM Health NV, is a biopharmaceutical company focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health was incorporated early 2020 by MRM Technologies, a Center of Expertise for microbiome research based in the biotech cluster in Ghent, in a joint venture with the Flemish Institute ofBiotechnology (VIB), an excellence-based entrepreneurial life sciences research institute in Flanders, Belgium, that focuses on translating basic scientific results into pharmaceutical, agricultural and industrial applications.
  • Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Show all investments...

Vives Louvain Technology Fund
VC Fund · Louvain-la-neuve, Vlaams-Brabant, Belgium · 9 investments in Belgium Biotechnology startups

Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B
  • Geography: Belgium, France, United States

Investor stats

  • Total investments: 25
  • Round size: Series A $491k–$46M; Series B $4.4M–$125M
  • Lead/follow: 4% lead, 96% follow
  • Last fund: May invest from a new fund soon — raised $37M in 2020

Portfolio highlights

  • BOTALYS — BOTALYS uses an innovative Biomimetic Indoor Farming technology to recreate the ideal wild conditions for rare botanicals to grow in. We develop pristine & potent botanical ingredients for the Nutraceutical and Cosmetic industries.
  • Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
  • Novadip Biosciences — Novadip Biosciences, an advanced biopharmaceutical company focused on new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.
Show all investments...

Limburgse Reconversie Maatschappij
VC Fund · Hasselt, Limburg, Belgium · 8 investments in Belgium Biotechnology startups

Oxygen for growth - LRM

Show more...

Investment focus

  • Industry: Information Technology, Software, Biotechnology
  • Stage:Seed, Series A
  • Geography: Belgium, United States, The Netherlands

Investor stats

  • Total investments: 91
  • Round size: Seed $494k–$5.2M; Series A $1.6M–$11M
  • Lead/follow: 13% lead, 87% follow

Portfolio highlights

  • Monsana — Monsana offers an AI-powered platform that connects eligible participants to relevant clinical trials throughout Europe.
  • ADLC — ADLC employs drone technology to deliver logistics services, allowing businesses to implement drone-based solutions without having to manage them in-house. The company is focused on enhancing last-mile delivery in maritime and offshore environments. ADLC now conducts drone delivery services in the Port of Antwerp in collaboration with SGS, atesting and certification company, and works with companies such as BASF. Its drones have reduced delivery times and environmental effect, boosting efficiency sixfold and lowering CO2 emissions by up to 80% for petrochemical sample deliveries.
  • Aidoptation — Aidoptation develops autonomous driving technology for dual-use applications in commercial automotive, police and first-responder vehicles, and defence-relevant environments.
Show all investments...

Gimv
VC Fund · Antwerpen, Antwerpen, Belgium · 8 investments in Belgium Biotechnology startups

Gimv, a trusted European investment company, helps mid-market businesses create sustainable value through growth capital and expertise across diverse sectors.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: Belgium, United States, France

Investor stats

  • Total investments: 169
  • Round size: Series A $3.3M–$79M; Series B $7M–$69M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: May invest from a new fund soon — raised $622M in 2010

Portfolio highlights

  • spineart — Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients.
  • ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
  • Anjarium Biosciences — Pioneering the next generation of non-viral gene therapy - by tackling more diseases, more precisely and in a more personalized way.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Capricorn Partners
VC Fund · Leuven, Vlaams-Brabant, Belgium · 8 investments in Belgium Biotechnology startups

Capricorn Partners is a unique independent manager of venture capital, growth capital and quoted equity funds

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Series A, Series B
  • Geography: Belgium, The Netherlands, United States

Investor stats

  • Total investments: 118
  • Round size: Series A $3.3M–$18M; Series B $5.3M–$42M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: Likely actively investing — fund raised in 2025

Portfolio highlights

  • Sensolus — Sensolus provides care-free tracking of your valuable non-powered assets directly from the cloud.Sensolus offers turnkey solutions for wireless, low-power context-aware sensing. Sensolus developed a personal product line of low-power tracker systems called STICKNTRACK.Sensolus is built upon many years of expertise in low-power networks,wireless sensor design, cloud-based sensor management, analytics, and applications.
  • Delft Advanced Biorenewables — We enable the bio-economy by improving the productivity of fermentations with our in-situ product recovery (ISPR) technology.
  • Trillium Renewable Chemicals — Trillium Renewable Chemicals manufactures chemicals from renewable feedstocks used in a variety of industrially important applications. The company was founded in 2021 and based in Knoxville, Tennessee.
Show all investments...

Vesalius Biocapital Partners
VC Fund · Strassen, Luxembourg, Luxembourg · 7 investments in Belgium Biotechnology startups

Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Belgium, Germany, France

Investor stats

  • Total investments: 61
  • Round size: Series A $3.8M–$20M; Series B $4.4M–$27M; Series C $7M–$100M
  • Lead/follow: 43% lead, 57% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Nutrium — Nutrium is the most up-to-date nutrition software for dietitians and nutritionists to manage their nutrition business with nutritional assessment, meal planning and progress tracking.
  • ENYO Pharma — ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials.
  • Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Show all investments...

Newton Biocapital
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 7 investments in Belgium Biotechnology startups

Our mission is to mature innovation and support the growth of our portfolio companies to create value for patients, society, local ecosystems, and investors.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Series A, Seed
  • Geography: Belgium, Japan, France

Investor stats

  • Total investments: 22
  • Round size: Seed $2.7M–$3.2M; Series A $6.1M–$84M
  • Lead/follow: 68% lead, 32% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Bioxodes — Bioxodes is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics to prevent thrombotic events without hemorrhagic risk.
  • Tensegrity Pharma — Tensegrity Pharma is the developer of a novel drug designed to minimize bottlenecks and provide innovative value to patients.
  • Augustine Therapeutics — Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.
Show all investments...

EQT Life Sciences
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 6 investments in Belgium Biotechnology startups

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, The Netherlands, Switzerland

Investor stats

  • Total investments: 182
  • Round size: Series A $6.9M–$77M; Series B $12M–$110M; Series C $12M–$165M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: Likely still investing — raised $266M in 2023

Portfolio highlights

  • LUMA Vision — OneProjects is an Irish-German cardiac imaging specialist.
  • Neurent Medical — Discover NEUROMARK, a minimally invasive solution for Chronic Rhinitis that targets the posterior nasal nerve to provide lasting symptom relief.
  • Rotation Medical — Rotation Medical Inc. manufactures and markets a collagen scaffold for rotational cuff disease in Minnesota. The company was formerly known as Denali Medical Inc. and changed its name to Rotation Medical Inc. in March 2010. Rotation Medical was founded in 2009 and headquartered in Plymouth, Minnesota.
Show all investments...

Sambrinvest
VC Fund · Gosselies, Hainaut, Belgium · 6 investments in Belgium Biotechnology startups

Sambrinvest is an active venture capital player in the region of Charleroi - Thuin.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: Belgium, France, Spain

Investor stats

  • Total investments: 39
  • Round size: Seed $544k–$24M; Series A $411k–$46M; Series B $4.4M–$44M
  • Lead/follow: 10% lead, 90% follow

Portfolio highlights

  • Sunrise — Sunrise aims to bring simple answers to millions of people suffering from sleep disorders.We have developed a 3-gram sensor to diagnose sleep with gold standard quality. The technology offers a revolutionary new way to measure brain commands at night, with published clinical results never seen before. Studies demonstrate Sunrise is as accurate asin-lab sleep studies, at a fraction of the cost.Affecting one in three people, sleep disorders are extremely common. Sleep apnea is the most prevalent disease with almost 1 billion persons concerned. This condition leads to great body damage over time and yet remains undiagnosed in 80% of the cases.Patients, caregiver and insurers stand to benefit greatly from a solution to current highly cumbersome, expensive and time-consuming diagnostics systems.
  • Vertical Compute — Vertical Compute offers chiplet-based technology that cuts data movement to achieve up to 80% energy savings.
  • Enodia Therapeutics — Enodia Therapeutics pioneers targeted protein degradation at the Sec61 translocon, developing small-molecule therapies for inflammatory and autoimmune diseases.
Show all investments...

KBC
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 4 investments in Belgium Biotechnology startups

KBC Private Equity - the investment company of KBC Group - provides development capital and finances buy-outs to medium-sized companies in Belgium and in Central and Eastern Europe, KBC's home markets.Boasting an experienced team of 28 people, it has more than 60 active investments in portfolio with a market value in excess of EUR 400million.KBC Private Equity aims to become one of the leading private equity providers on KBC Group's home markets. As an active shareholder with a long-term perspective, KBC Private Equity is involved in taking strategic decisions and providing support to management teams.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, FinTech
  • Stage:Seed, Series A, Series B
  • Geography: Belgium, United States, The Netherlands

Investor stats

  • Total investments: 33
  • Round size: Seed $549k–$8.2M; Series A $2.9M–$65M; Series B $33M–$44M
  • Lead/follow: 24% lead, 76% follow

Portfolio highlights

  • Rookoo — Rookoo is an AI-driven venue management software that talks to your customers, handles the intake, checks availability, fills your CRM or booking software, and hands off to your team for seamless follow-up.
  • Qivalis — Qivalis is a financial technology company designed for payments, settlements, and financial services.
  • Ion Beam Applications — Ion Beam Applications is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticalssegment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry.
Show all investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 4 investments in Belgium Biotechnology startups

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Germany, Switzerland

Investor stats

  • Total investments: 101
  • Round size: Seed $1.8M–$20M; Series A $3.8M–$34M; Series B $11M–$50M
  • Lead/follow: 48% lead, 52% follow
  • Last fund: May invest from a new fund soon — raised $250M in 2018

Portfolio highlights

  • Perfood — Perfood is a digital therapeutic startup that identifies what actions need to take on a personalized level, to prevent or fight diseases. Using sensors, lab results, and holistic analyses, they derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. They call this approach digitaltherapeutics. A digital solution that is just as effective as a drug. But without side effects.
  • ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
  • Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Show all investments...

Baekeland Funds
VC Fund · Gent, Gelderland, The Netherlands · 4 investments in Belgium Biotechnology startups

Baekeland Funds is a seed capital fund formed to invest in companies developed at the University of Ghent.

Show more...

Investment focus

  • Industry: Biotechnology, Hardware, Software
  • Stage:Series B, Series C
  • Geography: Belgium

Investor stats

  • Total investments: 8
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Caliopa — Caliopa NV develops and markets silicon photonics based optical transceivers for the data and telecommunications markets. The company was incorporated in 2010 and is based in Zwijnaarde, Belgium.
  • Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
  • Trinean — Unchained Labs helps biologics & gene therapy researchers break free from tools that don't cut it. Crank up your research with our problem-solving products.
Show all investments...

Omnes Capital
VC Fund · Paris, Ile-de-France, France · 4 investments in Belgium Biotechnology startups

Omnes VC is the Venture Capital arm of Omnes Capital, a leading private equity firm dedicated to energy transition and innovation with €4.8 billion in assets under management and a 20 year + experience in: venture capital, buyout & growth capital, private debt, renewable energy, co-investment, secondary funds of funds. Omnes Capital is fullyindependent.With 65 business sales including 14 IPOs carried out in 16 years, Omnes VC is one of the key players in France in financing innovative SMEs with expertise in both Technology and Healthcare sectors. Omnes VC has supported 120 companies and has invested more than €500M in businesses such as Scality, Novaled, BioVex, arGEN-X, Pixium, Blablacar.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Series B
  • Geography: France, Germany, United States

Investor stats

  • Total investments: 181
  • Round size: Series A $3.5M–$44M; Series B $4.4M–$53M
  • Lead/follow: 27% lead, 73% follow
  • Last fund: May invest from a new fund soon — raised $403M in 2020

Portfolio highlights

  • VSORA — VSORA provides high performance companion solutions combining AI and signal processing to enable autonomous driving and ADAS
  • SeqOne Genomics — Healthcare is undergoing a revolution, known as genomic medicine, that uses the patient’s genomic information to optimise treatment. This trend is accelerating thanks to the arrival of New Generation Sequencing (NGS) techniques that have reduced the cost of decoding genomic material while increasing the amount useful data obtained. However, NGShas had only limited impact on mainstream healthcare due to the difficulties in analyzing more and richer genomic data. SeqOne’s mission is to provide tools that enable the healthcare industry to analyse NGS genomic data better and more cost-effectively to provide universal access to genomic medicine.
  • Complix — Complix is a biopharmaceutical company focused on the discovery and development of Alphabodiesâ„¢, a novel class of biopharmaceuticals that offer significant advantages over existing protein based therapies. Alphabodiesâ„¢ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that aredifficult to reach with antibodies or other types of protein scaffolds. Due to their unique stability and versatility Alphabodiesâ„¢ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.
Show all investments...

Annie Vereecken
Angel · Antwerp, Antwerpen, Belgium · 4 investments in Belgium Biotechnology startups

Annie Vereecken

Show more...

Investment focus

  • Industry: Medical, Biotechnology, Hospital
  • Stage:Seed, Series A
  • Geography: Belgium

Investor stats

  • Total investments: 7
  • Round size: Seed $2M–$6M; Series A $8.2M–$27M
  • Lead/follow: 29% lead, 71% follow

Portfolio highlights

  • Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
  • LynxCare — Continuously improving patient outcomes with previously unavailable insights. Find out more here.
  • Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Droia Ventures
VC Fund · Luxembourg, Luxembourg, Luxembourg · 4 investments in Belgium Biotechnology startups

Droia Ventures is a specialist investor, dedicated to making an impact and save patient lives. We invest in the most promising life science companies.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Belgium, The Netherlands

Investor stats

  • Total investments: 39
  • Round size: Series A $15M–$75M; Series B $29M–$89M; Series C $75M–$125M
  • Lead/follow: 33% lead, 67% follow
  • Last fund: May invest from a new fund soon — raised $241M in 2021

Portfolio highlights

  • Actio Biosciences — At Actio, we are leveraging advances in genetics and precision medicine to develop life-changing treatments that target underlying shared biology between rare and common diseases. We are applying expertise in genetics, drug discovery, and data sciences to pinpoint targets that not only cause rare diseases with high unmet need, but that also hold promise in more common indications.
  • Protego Biopharma — Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California.
  • Unnatural Products — Unnatural Products is a startup pairing AI with chemistry to create treatments for drug targets. Its AI-enhanced technology platform creates entirely new drugs by engineering passively permeable, macrocyclic peptides that access traditionally undruggable targets.Unnatural Products was founded in 2017 and is headquartered in Santa Cruz,California.
Show all investments...

Spinventure
VC Fund · Angleur, Liege, Belgium · 4 investments in Belgium Biotechnology startups

Spinventure supports the creation of spin-off companies that aim to industrialize and commercialize the result of scientific research. Spinventure was born from a collaboration between MEUSINVEST and the University of Liège. It is headquartered in Angleur, Belgium.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A
  • Geography: Belgium

Investor stats

  • Total investments: 6
  • Round size: Series A $768k–$15M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Dim3 — Improve patients outcome - Deliver actionable insights - Save healthcare costs
  • Elysia — Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
  • Convert Pharmaceuticals — Convert Pharmaceuticals develops prodrugs that are inert upon administration to patients, but transform into potent anti-cancer agents upon entering tumors.
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 4 investments in Belgium Biotechnology startups

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 351
  • Round size: Series A $9M–$125M; Series B $13M–$135M; Series C $30M–$118M
  • Lead/follow: 40% lead, 60% follow
  • Last fund: May invest from a new fund soon — raised $165M in 2018

Portfolio highlights

  • Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
  • IVERIC bio — IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inheritedretinal diseases.
  • Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Show all investments...

Inventures SA
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 3 investments in Belgium Biotechnology startups

Inventures is a European venture capital fund that builds a better world through a portfolio of investments in sustainable businesses.The firm has two funds: Inventures I & Inventures II.Inventures was created to support early stage smart and innovative European businesses, to support sustainable job growth and empower entrepreneurs.Inventures empowers citizenship co-investments through a crowdfunding platform, MyMicroInvest.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Series A, Seed
  • Geography: Belgium, France, United Kingdom

Investor stats

  • Total investments: 46
  • Round size: Seed $82k–$2.2M; Series A $411k–$13M
  • Lead/follow: 9% lead, 91% follow
  • Last fund: May invest from a new fund soon — last raise in 2016

Portfolio highlights

  • BiOceanOr — BiOceanOr harnessed the power of Marine Biology and AI to deliver bio-guided services that optimize fish welfare and fish growth, while supporting aquaculture sustainability standards
  • myskillcamp — Myskillcamp is a digital learning platform and educational design support service. Myskillcamp supports their customers in the digital transformation of their company and the launch of their Digital Learning project. From the audit of needs to the design of engaging educational devices, through a pilot phase, they make a point of honor to adapt thedigital to the specificities of each and give it meaning.With their online platform, businesses can manage their learner communities and connect all their partners in one place. Their tool also allows businesses to structure training spaces by skills, trades, brands within camps. In parallel, businesses can create educational content from scratch, select a map in their marketplace, or plan sessions in-class. Businesses can organize the distribution of their training to a single learner or to a whole group.
  • Octave — A sustainable, cost-effective and reliable energy storage system with second-life batteries from electric vehicles.
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 3 investments in Belgium Biotechnology startups

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 200
  • Round size: Series A $19M–$176M; Series B $16M–$155M; Series C $19M–$113M
  • Lead/follow: 52% lead, 48% follow
  • Last fund: Likely actively investing — fund raised in 2024

Portfolio highlights

  • Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
  • Inflazome — Situs gacor premium Megawin188 paling banyak di minati oleh semua kalangan karena pecah selayar tanpa henti dan memiliki tampilan yang sangat memanjakan mata.
  • Beacon Therapeutics — Beacon aids in restoring and improving the vision of patients with ophthalmic gene therapy. Find out more.
Show all investments...

VIVES Funds
VC Fund · Wavre, Brabant Wallon, Belgium · 3 investments in Belgium Biotechnology startups

VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Seed, Series B
  • Geography: Belgium, France, Switzerland

Investor stats

  • Total investments: 10
  • Round size: Seed $2.9M–$5.5M; Series A $18M–$165M; Series B $34M–$132M
  • Lead/follow: 20% lead, 80% follow

Portfolio highlights

  • Bionyra — Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases.
  • Generare — Generare decodes microbial genomes to generate novel, high-quality molecular data for drug discovery. 200+ new molecules characterized and growing.
  • Nuclidium — NUCLIDIUM is a clinical-stage radiopharmaceutical company that develops novel radionuclide PET tracers for precision diagnostics. Using copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company is creating a differentiated platform with the potential to overcome existing limitations in radiotheranostics.
Show all investments...

Agri Investment Fund
VC Fund · Leuven, Vlaams-Brabant, Belgium · 3 investments in Belgium Biotechnology startups

AgroSavfe nv, a Belgium-based agro-biotech company

Show more...

Investment focus

  • Industry: Biotechnology, Agriculture, AgTech
  • Stage:Series B, Seed, Series A
  • Geography: Belgium, Switzerland, United Kingdom

Investor stats

  • Total investments: 18
  • Round size: Seed $3.7M–$11M; Series A $8.4M–$9.3M; Series B $4.4M–$24M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • Animab — Animal Health Company
  • Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
  • Rainbow Crops — Rainbow Crops is a next-generation Agtech company developing climate-resilient, high-performing crop varieties.
Show all investments...

Fountain Healthcare Partners
VC Fund · Dublin, Dublin, Ireland · 3 investments in Belgium Biotechnology startups

Fountain Healthcare Partners is an Irish based life science venture capital fund. Fountain is exclusively focused on the life science sector. Specific areas of interest to them are: specialty pharma, medical devices, biotechnology and diagnostics. They will deploy the majority of their capital in Europe with a strong focus on Ireland.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Ireland, United States, France

Investor stats

  • Total investments: 50
  • Round size: Series A $6.6M–$43M; Series B $5.5M–$68M; Series C $3.3M–$110M
  • Lead/follow: 42% lead, 58% follow
  • Last fund: May invest from a new fund soon — raised $128M in 2019

Portfolio highlights

  • Palyon Medical — Palyon Medical Corporation is a medical device company developing technologies for the treatment of chronic pain, spasticity and other neurological diseases.
  • Neuromod Devices — Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation.We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control oftheir own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle.Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'.
  • Ermium Therapeutics — Ermium Therapeutics is a biotech company developing innovative therapies for auto-immune diseases, based on a breakthrough discovery showing that CXCR4 is a master regulator of inflammation.Ermium Therapeutics was founded in June 2019 by Jean-Philippe HERBEUVAL, Kurma Partners, Idinvest Partners, Domain Therapeutics and Erganeo. The company isbased in Paris and has signed a worldwide exclusive license agreement on intellectual property from CNRS and University Paris Descartes (France) through an agreement with Erganeo, which supported the maturation of the project in an academic setting. In addition, Ermium Therapeutics recently won the innovation i-Lab 2019 award from the French Ministry of Research and Higher Education.
Show all investments...

Fund+
VC Fund · Leuven, Vlaams-Brabant, Belgium · 3 investments in Belgium Biotechnology startups

Fund+ is a venture capital firm that invests in companies operating in the diagnostics, therapeutics, medical devices, and life science sectors. The firm wants to create sustainable shareholders' value, contribute to the development of a leadership position in the life sciences sector, and generate a tangible, beneficial societal impact.Fund+ was established in 2015 and is based in Leuven, Belgium.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: Belgium, United States, Spain

Investor stats

  • Total investments: 32
  • Round size: Series A $11M–$44M; Series B $21M–$125M; Series C $11M–$401M
  • Lead/follow: 28% lead, 72% follow

Portfolio highlights

  • Ona Therapeutics — Ona Therapeutics is a biotech company that specializes in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. Founded in 2019 by Salvador Aznar-Benitah and Valerie Vanhooren, it was a spin-off from ICREA and Advanced Studies, and the IRB Institute for Research in Biomedicine.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
  • TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Show all investments...

Mérieux Equity Partners
VC Fund · Lyon, Rhone-Alpes, France · 3 investments in Belgium Biotechnology startups

Mérieux Equity Partners (“MxEP”) is a management company dedicated to venture, growth and LBO investments in the healthcare and nutrition sectors. MxEP actively supports entrepreneurs and industrial companies with differentiated products and services, by providing privileged access to its expertise and international network. MxEP currently managesmore than €600m AUM and has recently launched a new vehicle MP3 of €350m dedicated to growth/LBO.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series A, Private Equity
  • Geography: France, United States, Belgium

Investor stats

  • Total investments: 57
  • Round size: Series A $5.7M–$22M; Private Equity $22M–$150M
  • Lead/follow: 37% lead, 63% follow
  • Last fund: May invest from a new fund soon — raised $417M in 2020

Portfolio highlights

  • DeepUll — DeepUll is a biotech company that focuses its activity on the development of a new diagnostic system for early-stage sepsis condition. DeepUll’s proposal is based on quickly identifying the pathogens and offering the antibiogram within a few hours on the one hand, and on using the data and learning about the patient’s immunological and functionalstatus on the other. The system allows doctors to predict the future appearance and evolution of sepsis within a short period of time and thus provide a suitable clinical response even before the symptoms arise.
  • Ceva Santé Animale — Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs.
  • CorFlow Therapeutics — CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
UCB Ventures
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 3 investments in Belgium Biotechnology startups

UCB Ventures is a €150 million strategic corporate venture fund

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Seed
  • Geography: United States, Belgium, Spain

Investor stats

  • Total investments: 20
  • Round size: Seed $1.8M–$6.6M; Series A $6.6M–$75M; Series B $9.4M–$135M
  • Lead/follow: 40% lead, 60% follow

Portfolio highlights

  • SonoThera — Explore therapeutic ultrasound for non-invasive, targeted genetic medicine delivery that improves precision and biodistribution. Learn more.
  • Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Show all investments...

AdBio partners
VC Fund · Paris, Ile-de-France, France · 3 investments in Belgium Biotechnology startups

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: France, Spain, Belgium

Investor stats

  • Total investments: 32
  • Round size: Seed $2.2M–$18M; Series A $18M–$37M
  • Lead/follow: 41% lead, 59% follow
  • Last fund: Likely still investing — raised $116M in 2021

Portfolio highlights

  • Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
  • ARTHEx Biotech — ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing advanced RNA treatments against genetic diseases.
  • Integra Therapeutics — Integra Therapeutics is a developer of next generation of gene editing tools to cure diseases.
Show all investments...

SFPIM
VC Fund · Brussel, Brussels Hoofdstedelijk Gewest, Belgium · 3 investments in Belgium Biotechnology startups, 7 in the past 12 months

SFPIM investment firm that invests in technology and infrastructure.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, AgTech
  • Stage:Series A, Venture - Series Unknown
  • Geography: Belgium, France, Switzerland

Investor stats

  • Total investments: 25
  • Round size: Series A $8.6M–$57M; Venture - Series Unknown $11M–$251M
  • Lead/follow: 32% lead, 68% follow

Portfolio highlights

  • banqUP — BanqUP is an API-driven platform for open banking solutions, allowing for banks and fintech companies to access a number of European banking APIs. BanqUP helps TPPs and banks quickly access open banking ecosystem and analyze banking data, allowing them to create bold and innovative solutions, as well as cross-sell and up-sell their existingproducts.
  • D-CRBN — CO2 recycling for industrials
  • Biotalys — Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium.
Show all investments...

BioGeneration Ventures
VC Fund · Naarden, Noord-Holland, The Netherlands · 3 investments in Belgium Biotechnology startups

Shaping new life-science ventures.

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Health Care
  • Stage:Series A, Seed
  • Geography: The Netherlands, United States, Belgium

Investor stats

  • Total investments: 63
  • Round size: Seed $1.1M–$50M; Series A $5.3M–$86M
  • Lead/follow: 29% lead, 71% follow
  • Last fund: May invest from a new fund soon — raised $148M in 2021

Portfolio highlights

  • Dualyx — Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
  • Azafaros — Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
  • Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is
Show all investments...

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 2 investments in Belgium Biotechnology startups

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, United States, United Kingdom

Investor stats

  • Total investments: 319
  • Round size: Series A $6.6M–$70M; Series B $10M–$109M; Series C $12M–$100M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — raised $200M in 2023

Portfolio highlights

  • Myricx Bio — Myricx Pharma is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.
  • GFBiochemicals — GFBiochemicals is the only company to produce levulinic acid at commercial scale directly from biomass.In 2008, a group of biobased chemical experts saw the significant potential of levulinic acid to replace petroleum-based products across a range of market sectors. GFBiochemicals was founded to develop the production technology needed for thisrevolution in chemicals and biofuels.GFBiochemicals demonstrated these breakthrough technologies in the Caserta plant, in partnership with the University of Pisa and the Polytechnic University of Milan. This commercial-scale plant was retrofitted with new conversion, recovery and purification technology.
  • Forth Therapeutics — Forth Therapeutics is a biotechnology company dedicated to advancing precision treatments for fibrosis.
Show all investments...

HTGF (High-Tech Gruenderfonds)
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 2 investments in Belgium Biotechnology startups

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 497
  • Lead/follow: no public data

Portfolio highlights

  • BTRY — BTRY is a spin-off of EMPA and ETH and is developing the industry's first energy-dense solid-state battery, using sophisticated semiconductor manufacturing technologies.
  • Zeeg — Create a customized landing page in just a few clicks and let your customers easily book appointments with you.
  • viboo — viboo offers self-learning predictive control on the basis of physics-informed Machine Learning as a cloud service to smart-thermostat and building automation companies.
Show all investments...

Sofinnova Investments
VC Fund · Menlo Park, California, United States · 2 investments in Belgium Biotechnology startups

Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series B, Series A, Series C
  • Geography: United States, France, Switzerland

Investor stats

  • Total investments: 217
  • Round size: Series A $7.3M–$115M; Series B $15M–$150M; Series C $15M–$94M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $650M in 2016

Portfolio highlights

  • NextCure — NextCure is a biopharmaceutical company focused on discovering and developing next generation immuno-oncology-based drugs. The Company is applying its proprietary platforms and know-how to identify novel and biologically relevant targets and develop first-in-class immunotherapy products.
  • Spark Therapeutics — Breakthrough science. One moment, one day, one person at a time.
  • Marinus Pharmaceuticals — Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development of ganaxolone, offering a new mechanism of action with demonstrated safety and convenient dosing for patients affected by epilepsy and CNS disorders.
Show all investments...

Qbic
VC Fund · London, England, United Kingdom · 2 investments in Belgium Biotechnology startups

Qbic is the result of a lot of thinking, debating and sketching of what a city hotel could be; one that breaks the rules and makes people smile.An astonishing level of change has swept through the world over the last few years. But the hotel experience is no different than it’s ever been: stuffy, over-priced and lacking soul. They’re here tochange all that. they’re curious, imaginative and friendly, and they think there are lots of people just like us seeking a hotel with personality in the middle of the city.They believe in something better than what’s currently out there. A place that celebrates life rather than sucks life out of it. A hotel that’s built on creativity and a belief that you don’t have to accept the conventional. Somewhere that sends you away with fun stories and ideas, and is easy on your pocket.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, AgTech
  • Stage:Seed, Series B
  • Geography: Belgium

Investor stats

  • Total investments: 7
  • Round size: Seed $3.7M–$11M; Series B $7.5M–$12M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • moveUP — Ontvang medische zorg op afstand voor en na uw operatie. moveUP is gespecialiseerd in de begeleiding van knie- en heupoperaties.
  • Axithra — Axithra provides therapeutic medication monitoring and measures beta-lactam antibiotic concentrations in blood.
  • Cascador Health — Cascador Health bridges the gap between sources and users of healthcare data. Using curated, validated and anonymized RWD allows healthcare providers and life science industry to gain insights and provide better care.
Show all investments...

Capital-E
VC Fund · Washington, District of Columbia, United States · 2 investments in Belgium Biotechnology startups

Leading venture capital fund with exclusive focus on micro/nano-electronics and advanced materials

Show more...

Investment focus

  • Industry: Software, Manufacturing, Semiconductor
  • Stage:Series B, Series A
  • Geography: Belgium, United States, Germany

Investor stats

  • Total investments: 19
  • Round size: Series A $3.3M–$26M; Series B $7.5M–$13M
  • Lead/follow: 26% lead, 74% follow

Portfolio highlights

  • Accelleran — Accelleran is pioneering a disruptive approach to the delivery of cost-effective, carrier and mission-critical grade TDD and FDD Small Cell networks through its focus on software quality and partnerships with volume manufacturers.Accelleran provides LTE Small Cell software and LTE Small Cell product solutions which address the real-worldchallenges of volume deployment of Small Cells. We offer turnkey solutions and unique experience on the challenges of integrating cellular technology on low cost, yet powerful platforms and architectures. Accelleran offers its customers solid and dependable system solutions, backed by the support of our unparalleled expertise.Accelleran’s technology is genuinely independent from any HW platform and enables operators to invest once in the integration and validation of a common software base that can be deployed across different segments, platforms and Small Cell architectural approaches to enable a truly integrated HetNet.
  • Silicon Line — Munich, Germany-based Silicon Line (www.silicon-line.com) is the unchallenged world leader in developing and providing innovative ultra-low-power optical link technology that enables the use of thin, long, lightweight and very high speed ‘active’ optical cables for a wide array of consumer electronics products – including TVs, set-top boxes, videogame consoles, augmented reality (AR) and virtual reality (VR) headsets and related devices – as well as commercial and industrial applications. ‘Active’ refers to powered electronics integrated within the cable.Clear evidence of Silicon Line’s global leadership in ultra-lower-power optical technology can be seen not only by its steadily evolving line of leading-edge and industry-first products – with more than 25 different products now in use – but also in its pivotal role within the HDMI Forum, where it has successfully led efforts to enhance support for active optical cable technology standards in the latest specification, HDMI 2.1.Founded in 2005 as an outsource integrated circuit (IC) design house, Silicon Line quickly developed proven expertise in ultra-low-power, analog and mixed-signal chip design. Billions of ICs based on its designs have been used in products of major brand-name manufacturers.
  • Silicon Mobility — Our solution enables carmakers to improve EV and HEV energy efficiency, increase range and accelerate charging time while reducing cost.
Show all investments...

Theodorus III
VC Fund · 2 investments in Belgium Biotechnology startups

Theodorus is the spin-off fund of Université Libre de Bruxelles that invests ininvest in early stage projects based on proprietary disruptive technologies.

Show more...

Investment focus

  • Industry: Health Care, Life Science, Biotechnology
  • Stage:Seed, Series A
  • Geography: Belgium, Canada, France

Investor stats

  • Total investments: 15
  • Round size: Seed $3.7M–$18M; Series A $2.2M–$6.6M
  • Lead/follow: 20% lead, 80% follow

Portfolio highlights

  • DrugBank — DrugBank augments human intelligence to improve the world’s health. Our suite of products are powered by the world’s most complete and up-to-date pharmaceutical knowledge database. It includes everything there is to know about drugs and how they work in the body. We enable companies to improve healthcare delivery through precision medicine orclinical software applications, as well as uncover insights through data science in drug discovery. Our knowledge base can be integrated into software solutions to help achieve clinical intelligence. Companies can easily scale their usage through our API and launch faster with flexible data modules. By providing users with advanced insights and the right information at the right time, users are empowered to make better health decisions.Our extensive, structured datasets are used to discover novel drug candidates, identify drug repurposing opportunities, and build predictive machine learning models. Companies working with data science can find answers quickly and get drugs to market faster with our evidence-based drug information. Lastly, our publicly available resource, DrugBank Online, is free-to-use with limited datasets available for download for academic and non-commercial researchers. DrugBank has been cited in over 13,000 academic publications and is used by millions of researchers and health professionals globally.
  • Simmunome AI — We use AI to create accurate, comprehensive disease models using multi-omic data to determine the probability of success of a drug. Our clinical trial simulations allow you to gain insights, make go/no-go decisions, and de-risk your pipeline, getting you to market faster and reducing your R&D co
  • Ability biologics — Ability develops innovative, targeted, immune modulating biotherapeutics to address unmet medical needs in patients with cancer and autoimmune diseases.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Quest for Growth
VC Fund · Leuven, Vlaams-Brabant, Belgium · 2 investments in Belgium Biotechnology startups

Quest for Growth (QGPLF) is an Internet company located in 19 Lei, Leuven, Flanders, Belgium.

Show more...

Investment focus

  • Industry: Biotechnology, Hardware, Software
  • Stage:Series B, Series C
  • Geography: Belgium, France, The Netherlands

Investor stats

  • Total investments: 24
  • Round size: Series B $510k–$65M; Series C $8.1M–$21M
  • Lead/follow: 4% lead, 96% follow

Portfolio highlights

  • Qpinch — Our patented QHT - Qpinch Heat Transformer - technology recovers and transforms waste heat into carbon neutral process heat.
  • Finquest — Tap into the largest private company database in the world to change the way you find and connect with M&A targets using Data, AI, & People.
  • Confo Therapeutics — Confo Therapeutics is a clinical-stage company committed to accelerating novel GPCR-directed medicines for metabolic & endocrine diseases.
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 2 investments in Belgium Biotechnology startups

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, United Kingdom, Switzerland

Investor stats

  • Total investments: 171
  • Round size: Seed $2.4M–$22M; Series A $5.6M–$49M; Series B $15M–$100M
  • Lead/follow: 38% lead, 62% follow

Portfolio highlights

  • iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
  • Future Fertility — OUR AI-POWERED ASSESSMENTS GUIDE PERSONALIZED FERTILITY TREATMENT DECISIONS IN OVER 180 CLINICS ACROSS 32 COUNTRIES
  • ApoGen Biotechnologies — ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapieseventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Show all investments...

Pontifax
VC Fund · Herzliya, Tel Aviv, Israel · 2 investments in Belgium Biotechnology startups

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, Israel, France

Investor stats

  • Total investments: 113
  • Round size: Series A $6.3M–$110M; Series B $20M–$128M; Series C $12M–$101M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — raised $14M in 2020

Portfolio highlights

  • ArQule — ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company employs technologies, such as its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs. The Company's product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).
  • Graviton Bioscience — Curing Disease through Restored Homeostasis
  • Applied Immune Technologies — Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.
Show all investments...

Thuja Capital
VC Fund · Utrecht, Utrecht, The Netherlands · 2 investments in Belgium Biotechnology startups

Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Series A, Seed
  • Geography: The Netherlands, Belgium, United States

Investor stats

  • Total investments: 54
  • Lead/follow: no public data

Portfolio highlights

  • Pan Cancer — Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer.
  • Synerkine Pharma — Synerkine Pharma. Connecting Cytokines for the benefit of patients.
  • Artica Therapeutics — Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food.
Show all investments...

Eli Lilly
VC Fund · Indianapolis, Indiana, United States · 2 investments in Belgium Biotechnology startups

Lilly is a medicine company that puts health above all. Learn about our medicines, view condition support, find care, and much more.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 111
  • Lead/follow: no public data

Portfolio highlights

  • Excelsior Sciences — Rebuilding the World, From the Bottom Up
  • Syndeio Biosciences — Syndeio Biosciences is a clinical-stage biotechnology company focused on developing therapies to restore and enhance synaptic health in central nervous system (CNS) disorders.
  • Affinia Therapeutics — Affinia Therapeutics is expanding what's possible in adeno-associated virus (AAV) gene therapy today and bringing transformative medicines for people.
Show all investments...

SFPI-FPIM
VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium · 2 investments in Belgium Biotechnology startups

The Federal Holding and Investment Company (SFPI-FPIM) centrally manages the federal government’s shareholdings, cooperates with the government on specific projects and pursues its own investment policy in the interests of the Belgian economy.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical Device
  • Stage:Series B, Series A
  • Geography: Belgium, United States, France

Investor stats

  • Total investments: 37
  • Lead/follow: no public data

Portfolio highlights

  • Cohabs — We create sustainable & community-driven shared homes around the world for young workers and interns. Join our community.
  • Univercells — We are biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.
  • Tangent Works — Create predictive models in seconds for faster and better forecasting & anomaly detection with TIM InstantML.
Show all investments...

GoBeyond
VC Fund · Zürich, Zurich, Switzerland · 2 investments in Belgium Biotechnology startups

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Show more...

Investment focus

  • Industry: Information Technology, Medical, Software
  • Stage:Seed, Series A
  • Geography: Switzerland, Germany, United Kingdom

Investor stats

  • Total investments: 163
  • Lead/follow: no public data

Portfolio highlights

  • Stylect — Stylect is a mobile app to to help women discover their perfect shoe. They aggregate products from multiple websites and based on users' preferences (that they gather through a hot-or-not interface), they recommend better products. Their users are able to keep track of and buy the products they like and receive notifications whenever a productthey love goes on sale. Finally, They use geolocation to let their users know when a shoe is selling in a store nearby.
  • Fastree3D — Fastree3D imaging sensors help recognize and measure distance to fast moving objects in real-time, enabling driving assistance or autonomous navigation. Fastree3D SA is a fabless semiconductor company, spin-off from EPFL Lausanne, Switzerland founded in September 2013 (UID CHE-291.330.490). The company subsidiary Fastree3D B.V. performs researchwith TU-Delft, Netherlands (KvK 58866973).
  • Prestodiag — Prestodiag develops, manufactures and sells innovative solutions for rapid detection of bacteria. Their analytical solutions are based on an innovative optics technology called Surface Plasmon Resonance imaging and allow detection and identification of pathogenic bacteria such as Salmonella, Listeria or E.coli. They provide users with a result injust a few hours instead of 1 to several days. Their market is primarily the food safety sector, and also on medical and environmental applications.
Show all investments...

Luc Vauterin
Angel · 2 investments in Belgium Biotechnology startups

Luc Vauterin - Board Member @ ONTOFORCE

Show more...

Investment focus

  • Industry: Life Science, Data Integration, Data Visualization
  • Stage:Seed, Series A
  • Geography: Belgium

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • ONTOFORCE — ONTOFORCE creates and implements pioneering semantic search technology for information management. Our user-friendly data search platform DISQOVER builds uniquely intelligent links between heterogeneous data sources, allowing everybody to become a data scientist.
Show all investments...

invest.bw
VC Fund · Louvain-la-neuve, Vlaams-Brabant, Belgium · 2 investments in Belgium Biotechnology startups

invest.bw is a venture capital firm.

Show more...

Investment focus

  • Industry: Health Care, Neuroscience
  • Stage:Seed
  • Geography: United States

Investor stats

  • Total investments: 4
  • Lead/follow: no public data

Portfolio highlights

  • BiocSol — BiocSol focus on sustainable microbial-based crop protection.
  • neuroClues — An easy-to-use eye-tracking environment to help practitioners instantaneously quantify their clinical exam
  • ARK Capture Solutions — ARK Capture Solutions is a cleantech company that specializes in decarbonization solutions to record low energy consumption.
Show all investments...

Johnson & Johnson Innovation
VC Fund · Cambridge, Massachusetts, United States · 2 investments in Belgium Biotechnology startups, 11 in the past 12 months

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Israel, Switzerland

Investor stats

  • Total investments: 124
  • Round size: Series A $4.4M–$67M; Series B $10M–$150M; Series C $30M–$103M
  • Lead/follow: 31% lead, 69% follow

Portfolio highlights

  • SonoThera — Explore therapeutic ultrasound for non-invasive, targeted genetic medicine delivery that improves precision and biodistribution. Learn more.
  • Fesarius Therapeutics — Intelligently Patterned Native-State Hydrogel Wound Dressing for Dermal Tissue Regeneration...
  • TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates
Show all investments...

Biotechnology Investor funding in Belgium at a glance

Stats across 238 deals from 277 investors.

277
investors
in Belgium Biotechnology startups
238
deals
in Belgium Biotechnology startups
$6.6M
median round
in Belgium Biotechnology startups
38%
lead investors
lead at least one round
21%
Series A
most common funding stage
93/7
VC / Angel
share of investor count

Access all 277 investors in Belgium Biotechnology startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology Investors in Belgium investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 277 investors investing in Belgium Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists